Astrazeneca

(Image: Getty/Bong Hyunjung)

MedImmune will cease to exist after 30 years

By Ben Hargreaves

In full-year financials, AstraZeneca announced that its R&D arm, MedImmune, will be absorbed into the overall company as it restructures its R&D units into specific therapy areas.

Pharma appointments create controversy

Hired and Retired: Controversies at the top

By Ben Hargreaves

The new year has led to a new look to executive boards across the pharma industry, but the movement has arrived with a degree of intrigue in some cases.

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All suppliers